Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor signaling and prostate cancer progression

Although the new generation of androgen receptor (AR) antagonists like enzalutamide (ENZ) prolong survival of metastatic castration-resistant prostate cancer (CRPC), AR-driven tumors eventually recur indicating that additional therapies are required to fully block AR function. Since DNA topoisomeras...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Haolong, Xie, Ning, Gleave, Martin E., Dong, Xuesen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4653019/
https://www.ncbi.nlm.nih.gov/pubmed/26009876

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4653019/
https://www.ncbi.nlm.nih.gov/pubmed/26009876

Ejemplares similares